Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for pH Monitoring and Adjustment in Bioreactor Operations – V 2.0

Posted on By


Biosimilars: SOP for pH Monitoring and Adjustment in Bioreactor Operations – V 2.0


Standard Operating Procedure for pH Monitoring and Adjustment in Bioreactor Operations for Biosimilars

Department Biosimilars
SOP No. SOP/BS/069/2025
Supersedes SOP/BS/069/2022
Page No. Page 1 of 12
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To provide a standardized procedure for monitoring and adjusting pH in bioreactors during biosimilar manufacturing processes, ensuring optimal cell growth conditions and GMP compliance.

2. Scope

This SOP applies to all production bioreactors used in upstream processing of biosimilars, including stainless steel and single-use systems ranging from 10L to 2000L.

3. Responsibilities

  • Process Operators: Monitor pH in real time and perform adjustments as per protocol.
  • Maintenance Team: Calibrate pH probes and ensure operational status of pH control loops.
  • QA Personnel: Review logs and verify adherence to validated pH ranges.

4. Accountability

The Head of Upstream Production is accountable for maintaining pH control within the defined range and ensuring appropriate documentation and calibration status.

5. Procedure

5.1 Calibration of pH Probes

  1. Calibrate pH probes using 2-point calibration with certified buffer solutions (pH 4.0 and 7.0) prior to batch start (Annexure-1).
  2. Ensure calibration is logged and probe tags match bioreactor configuration.

5.2 Setpoint Configuration

  1. Set desired pH range on the bioreactor control panel (typically 6.8–7.2 for mammalian cells).
  2. Verify PID settings for acid/base addition systems are in automatic mode.

5.3 Real-Time pH Monitoring

  1. Monitor pH via bioreactor software interface every 2 hours.
  2. Log actual values, trends, and any deviation in the pH Monitoring Log (Annexure-2).
  3. If automated system is offline, perform manual sampling and check with handheld pH meter.

5.4 pH Adjustment Procedure

  1. If pH falls below setpoint:
    • Use sterile 1N NaOH for upward correction through automated or manual ports.
  2. If pH exceeds setpoint:
    • Use sterile 1N HCl or CO2 sparging for downward correction.
  3. Adjust slowly and monitor impact in 10-minute intervals to avoid overshoot.

5.5 Alarm Management

  1. In case of pH deviation beyond ±0.2 units:
    • Trigger alarm and initiate deviation handling (SOP/BS/050/2025).
    • Verify if probe fouling or drift occurred; perform re-calibration if required.

5.6 End-of-Run Procedure

  1. Record final pH and probe status in End-of-Run Summary (Annexure-3).
  2. Clean pH sensor as per SOP/BS/098/2025 and store in pH 4.0 buffer.

6. Abbreviations

  • PID: Proportional-Integral-Derivative
  • QA: Quality Assurance
  • GMP: Good Manufacturing Practice

7. Documents

  1. pH Probe Calibration Log – Annexure-1
  2. pH Monitoring Log Sheet – Annexure-2
  3. End-of-Run pH Summary – Annexure-3

8. References

  • ICH Q7 – Good Manufacturing Practice for Active Pharmaceutical Ingredients
  • WHO TRS 1010 – Guidelines on Biotherapeutics
  • SOP/BS/050/2025 – Deviation Handling
  • SOP/BS/098/2025 – pH Sensor Maintenance

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: pH Probe Calibration Log

Probe ID Calibration Date Buffer Used Calibrated By
PH-BR-01 03/05/2025 pH 4.0 & 7.0 Sunita Reddy

Annexure-2: pH Monitoring Log Sheet

Date Time Setpoint Actual pH Remarks
04/05/2025 12:00 7.0 7.02 Within limit

Annexure-3: End-of-Run pH Summary

Batch ID Final pH Deviation Noted Corrective Action
BR-109 6.98 No N/A

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Added Annexure-3 and CO₂ adjustment for high pH Process Optimization
See also  Biosimilars: SOP for Genetic Stability Testing - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: BA-BE Studies: SOP for Weekend and Holiday Subject Management – V 2.0
Next Post: Analytical Method Development: HPLC Gradient Method Development – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version